Scott Myers compensation by year
Viridian Therapeutics Summary Compensation Table · the one fiscal year held| Component | FY2023 |
|---|---|
| Salary | $549,475 |
| Bonus | $0 |
| Stock awards | $8,950,000 |
| Option awards | $26,786,134 |
| Non-equity incentive | $0 |
| Pension and deferred compensation | $0 |
| All other | $122,381 |
| Total | $36,407,990 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Viridian Therapeutics, Inc. DEF 14A filed April 26, 2024, accession 0001193125-24-115928, and prior-year filings.
How this page was built: the Viridian Therapeutics, Inc. filed document, accession 0001193125-24-115928. Every figure is read from that document and cited to the page and table it appears in. Filed April 26, 2024.
Viridian Therapeutics’s named executive officers, FY2023
as the company reported each| Named executive officer | Role | FY2023 total |
|---|---|---|
| Scott Myers · this page | Former President, Chief Executive Officer and Director | $36,407,990 |
| Stephen Mahoney | President, Chief Executive Officer | $12,479,521 |
| Seth Harmon | Senior Vice President of Finance and Accounting | $6,548,526 |
| Thomas Beetham | Chief Operating Officer | $4,761,401 |
| Jonathan Violin | Former President, Chief Executive Officer and Director | $2,211,072 |
Board service
Viridian Therapeutics board · FY2023How this board is paid
Company policy: Viridian Therapeutics pays directors a $40,000 cash retainer. As stated in Viridian Therapeutics's FY2023 proxy.
The full Viridian Therapeutics compensation record
free company briefThis page is one person within Viridian Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Viridian Therapeutics proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Viridian Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.